1. Home
  2. CALC vs KITT Comparison

CALC vs KITT Comparison

Compare CALC & KITT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CALC
  • KITT
  • Stock Information
  • Founded
  • CALC 2011
  • KITT 2014
  • Country
  • CALC United States
  • KITT United States
  • Employees
  • CALC N/A
  • KITT N/A
  • Industry
  • CALC Biotechnology: Pharmaceutical Preparations
  • KITT Industrial Machinery/Components
  • Sector
  • CALC Health Care
  • KITT Industrials
  • Exchange
  • CALC Nasdaq
  • KITT Nasdaq
  • Market Cap
  • CALC 32.4M
  • KITT 37.7M
  • IPO Year
  • CALC N/A
  • KITT N/A
  • Fundamental
  • Price
  • CALC $3.80
  • KITT $1.01
  • Analyst Decision
  • CALC Strong Buy
  • KITT
  • Analyst Count
  • CALC 2
  • KITT 0
  • Target Price
  • CALC $14.50
  • KITT N/A
  • AVG Volume (30 Days)
  • CALC 133.2K
  • KITT 1.9M
  • Earning Date
  • CALC 08-11-2025
  • KITT 08-12-2025
  • Dividend Yield
  • CALC N/A
  • KITT N/A
  • EPS Growth
  • CALC N/A
  • KITT N/A
  • EPS
  • CALC N/A
  • KITT N/A
  • Revenue
  • CALC N/A
  • KITT $1,508,374.00
  • Revenue This Year
  • CALC N/A
  • KITT $2,936.06
  • Revenue Next Year
  • CALC N/A
  • KITT N/A
  • P/E Ratio
  • CALC N/A
  • KITT N/A
  • Revenue Growth
  • CALC N/A
  • KITT N/A
  • 52 Week Low
  • CALC $1.42
  • KITT $0.82
  • 52 Week High
  • CALC $5.97
  • KITT $6.04
  • Technical
  • Relative Strength Index (RSI)
  • CALC 73.90
  • KITT 49.85
  • Support Level
  • CALC $3.37
  • KITT $0.95
  • Resistance Level
  • CALC $4.26
  • KITT $1.15
  • Average True Range (ATR)
  • CALC 0.41
  • KITT 0.09
  • MACD
  • CALC 0.21
  • KITT -0.00
  • Stochastic Oscillator
  • CALC 82.80
  • KITT 23.08

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.

About KITT Nauticus Robotics Inc.

Nauticus Robotics Inc develops fully electric autonomous robotic solutions for subsea applications. The company's business model includes using robotic systems for service, selling vehicles and components, and licensing related software to both the commercial and defense business sectors. The company's addressable markets include upstream, midstream, and downstream oil and gas, defense, offshore renewables, seafloor telecommunications, aquaculture, port security, oceanographic research, and subsea mining.

Share on Social Networks: